Immix Biopharma Inc (IMMX) - Total Liabilities
Based on the latest financial reports, Immix Biopharma Inc (IMMX) has total liabilities worth $11.45 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Immix Biopharma Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Immix Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. See IMMX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Immix Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Immix Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥666.33 Million |
|
Kid ASA
OL:KID
|
Norway | Nkr3.13 Billion |
|
Community Healthcare Trust Inc
NYSE:CHCT
|
USA | $588.75 Million |
|
Earth-Panda Advanced Magnetic Material Co Ltd
SHG:688077
|
China | CN¥1.63 Billion |
|
Intellian Technologies Inc
KQ:189300
|
Korea | ₩238.39 Billion |
|
Zinzino AB Series B
ST:ZZ-B
|
Sweden | Skr1.05 Billion |
|
VIP Industries Limited
NSE:VIPIND
|
India | Rs12.58 Billion |
|
Shanghai Morn Electric Equipment Co Ltd
SHE:002451
|
China | CN¥1.06 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Immix Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Immix Biopharma Inc (IMMX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immix Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immix Biopharma Inc (2019–2025)
The table below shows the annual total liabilities of Immix Biopharma Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.04 Million | +13.90% |
| 2024-12-31 | $9.70 Million | +160.54% |
| 2023-12-31 | $3.72 Million | +112.88% |
| 2022-12-31 | $1.75 Million | +765.33% |
| 2021-12-31 | $202.04K | -96.17% |
| 2020-12-31 | $5.27 Million | +14.84% |
| 2019-12-31 | $4.59 Million | -- |
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.